Is the excitement surrounding chipmaker Nvidia fading? As of Monday, shares of the tech giant were down 19% since the start ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

Merck dazzled with Phase 3 trial results for its PAH drug WINREVAIR, but the market responded with a collective shrug, ...

Merck’s latest clinical data puts a shiny new needle on its cancer blockbuster Keytruda, showing that a quick two-minute ...

Despite the broader market downturn, 10 individual stocks showed a strong performance during the trading session, with three ...

MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...